Disclosed herein is an engineered cell line comprising a modification in an ISG15 gene, wherein the modification in the ISG15 gene results in an increase in total viral particle production and/or infectious viral particle production as compared to a control cell line that is identical to the engineered cell line except for the modification in the ISG15 gene. Also disclosed herein are methods of increasing viral particle production and methods of identifying a gene for deletion in a cell or cell line.

Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag/pol protein, and methods of use thereof for delivery of the cargo to cells.

The present disclosure provides compositions comprising recombinant polynucleotides encoding Jurona virus, infectious particles, pharmaceutical compositions, and cells comprising the same, and methods and systems for making recombinant Jurona virus.

Enhanced virus-like particles (eVLPs), comprising a membrane comprising a phospholipid bilayer with one or more virally-derived glycoproteins on the external side; and a cargo disposed in the core of the eVLP on the inside of the membrane, wherein the eVLP does not comprise an exogenous gag/pol protein, and methods of use thereof for delivery of the cargo to cells.

The present invention relates to the field of upstream and downstream processing and provides a process for producing a purified rhabdovirus from a cell culture, preferably a purified oncolytic rhabdovirus and in particular a vesicular stomatitis virus, including pharmaceutical compositions comprising the rhabdovirus.